NCT04759768View on ClinicalTrials.gov

Pharmacokinetic Evaluation of Intranasal Nalmefene

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

May 17, 2021

Study Completion Date

May 24, 2021

Conditions
Pharmacokinetics
Interventions
DRUG

Nalmefene Hydrochloride

3mg nasal spray

DRUG

Nalmefene

1mg intramuscular injection

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors
All Listed Sponsors
lead

Opiant Pharmaceuticals Inc

INDUSTRY